PMV Pharmaceuticals, Inc.

Equities

PMVP

US69353Y1038

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
1.71 ^USD	+1.18%		+5.56%	-44.84%

Apr. 12	Jefferies Starts PMV Pharmaceuticals With Buy Rating, $5 Price Target	MT
Mar. 27	PMV Pharmaceuticals, Inc. Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220c-Positive Solid Tumors	CI

PMV Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021

November 12, 2021 at 07:22 am EST

PMV Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported net loss was USD 15.01 million compared to USD 8.76 million a year ago. Basic loss per share from continuing operations was USD 0.33 compared to USD 1.46 a year ago. For the nine months, net loss was USD 39.49 million compared to USD 23.99 million a year ago. Basic loss per share from continuing operations was USD 0.88 compared to USD 5.93 a year ago.

Latest news about PMV Pharmaceuticals, Inc.

Jefferies Starts PMV Pharmaceuticals With Buy Rating, $5 Price Target	Apr. 12	MT
PMV Pharmaceuticals, Inc. Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220c-Positive Solid Tumors	Mar. 27	CI
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer	Mar. 18	CI
North American Morning Briefing : Stock Futures -2-	Mar. 06	DJ
PMV Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
PMV Pharmaceuticals, Inc. Announces Workforce Reduction of Approximately 30%	Jan. 18	CI
PMV Pharmaceuticals Names Michael Carulli as CFO; Phase 2 Trial of Tumor Treatment on Track	Jan. 05	MT
PMV Pharmaceuticals, Inc. Announces Chief Financial Officer Changes	Jan. 05	CI
PMV Pharmaceuticals, Inc. Announces Executive Changes	Jan. 05	CI
Ladenburg Thalmann Initiates PMV Pharmaceuticals at Buy With $7 Price Target	Dec. 27	MT
PMV Pharmaceuticals, Inc.(NasdaqGS:PMVP) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
PMV Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
HC Wainwright Cuts Price Target on PMV Pharmaceuticals to $5 From $29, Maintains Buy Rating	23-10-16	MT
PMV Pharmaceuticals Says Updated Trial Data Show Cancer Therapy Induces Anti-Tumor Activity; Shares Fall	23-10-12	MT
PMV Pharmaceuticals, Inc. Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types with TP53 Y220C Mutation	23-10-12	CI
PMV Pharmaceuticals, Inc. to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics	23-09-20	CI
HC Wainwright Adjusts PMV Pharmaceuticals Price Target to $29 From $35, Maintains Buy Rating	23-08-11	MT
PMV Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
PMV Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
HC Wainwright Adjusts Price Target on PMV Pharmaceuticals to $35 From $36, Keeps Buy Rating	23-03-20	MT
PMV Pharmaceuticals, Inc.(NasdaqGS:PMVP) dropped from S&P Biotechnology Select Industry Index	23-03-20	CI
Oppenheimer Adjusts PMV Pharmaceuticals' Price Target to $15 From $28, Maintains Outperform Rating	23-03-02	MT
PMV Pharmaceuticals Proposes $200 Million Mixed Shelf Offering	23-03-02	MT
PMV Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-01	CI
HC Wainwright Adjusts PMV Pharmaceuticals' Price Target to $36 From $63, Keeps Buy Rating	22-11-17	MT

Chart PMV Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

PMV Pharmaceuticals, Inc. is a precision oncology company, which is engaged in discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a tumor suppressor protein known as the guardian of the genome, and normal, or wild type, p53 has the ability to eliminate cancer cells. It is leveraging its precision oncology platform to develop a pipeline of orally available, potent and highly selective small molecule product candidates that target p53 mutations or other p53-related cancers. Its lead product candidate, PC14586 (rezatapopt), is an orally available small molecule designed to potently and selectively correct p53 misfolding caused by a specific p53 mutation, Y220C, while sparing wild type p53. In preclinical studies, PC14586 has shown selective on-target activity, which functions in cells with the p53 Y220C mutation and exhibited robust anti-tumor activity evidenced by potent tumor growth inhibition and strong tumor regression as a single agent.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.71 USD

Average target price

5.667 USD

Spread / Average Target

+231.38%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PMV PHARMACEUTICALS, INC.	-44.84%	86.94M
IQVIA HOLDINGS INC.	+1.12%	43.84B
MODERNA, INC.	+6.77%	41.68B
LONZA GROUP AG	+45.26%	41.25B
CELLTRION, INC.	-11.96%	27.04B
ICON PUBLIC LIMITED COMPANY	+6.01%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.92%	18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.63%	12.29B
MEDPACE HOLDINGS, INC.	+27.16%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.30%	11.15B

Other Biotechnology & Medical Research